In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

End-To-End Support at Every Stage of Your Drug Development Journey
Brochures, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions

Towards A New Standard of Care with Aptar Pharma’s Digital Health
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Successfully Balancing The Needs of The Planet With The Needs of The Patient
Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Product Solutions

Extractables & Leachables for Injectable Formulations
Webinars, Pharmaceutical, Product Solutions, Innovation & Insights